Effect of infliximab induction therapy on secondary systemic amyloidosis associated with Crohn's disease: Case report and review of the literature

Journal of Gastrointestinal and Liver Diseases

Volumn 22, Issue 3, 2013, Pages 333-336

  Pukitis, Aldis ^a   Zake, Tatjana ^b   Groma, Valerija ^b   Ostrovskis, Evalds ^c   Skuja, Sandra ^b   Pokrotnieks, Juris ^b  

^a UNIVERSITY OF LATVIA   (Latvia)

^b RIGA STRADINS UNIVERSITY   (Latvia)

^c PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

Author keywords

Crohn's disease; Infliximab; Secondary systemic amyloidosis

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; MESALAZINE; PREDNISOLONE; SERUM AMYLOID A; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; AMYLOIDOSIS; ANEMIA; ARTICLE; ASCITES; CASE REPORT; CHRONIC KIDNEY DISEASE; COLON BIOPSY; COLONOSCOPY; CROHN DISEASE; DIARRHEA; ENTERIC FEEDING; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; INDUCTION CHEMOTHERAPY; KIDNEY BIOPSY; MALE; MALNUTRITION; NEPHROTIC SYNDROME; PARENTERAL NUTRITION; PROTEINURIA; RELAPSE; REPEATED DRUG DOSE; ANTAGONISTS AND INHIBITORS; BIOPSY; BLOOD; COMPLICATION; DRUG COMBINATION; IMMUNOLOGY; METABOLISM; PREDICTIVE VALUE; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; YOUNG ADULT;

AMYLOIDOSIS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BIOPSY; C-REACTIVE PROTEIN; CROHN DISEASE; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HUMANS; MALE; NEPHROTIC SYNDROME; PREDICTIVE VALUE OF TESTS; RENAL INSUFFICIENCY, CHRONIC; SERUM AMYLOID A PROTEIN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84884660998     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis 2001; 7: 295-300.
2. Greenstein AJ, Sachar DB, Panday AK, et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine 1992; 71: 261-270.
3. Weterman IT, Biemond I, Pena AS. Mortality and causes of death in Crohn's disease. Review of 50 years' experience in Leiden University Hospital. Gut 1990; 31: 1387-1390.
4. Obici L, Merlini G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly 2012; 142: w13580.
5. Iizuka M, Konno S, Horie Y, Itou H, Shindo K, Watanabe S. Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease. Gut 2006; 55: 744-745.
6. Bosca MM, Perez-Baylach CM, Solis MA, et al. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor. Gut 2006; 55: 294-295.
7. Park YK, Han DS, Eun CS. Systemic amyloidosis with Crohn's disease treated with infliximab. Inflamm Bowel Dis 2008; 14: 431-432.
8. Iizuka M, Sagara S, Etou T. Efficacy of scheduled infliximab maintenance therapy on systemic amyloidosis associated with Crohn's disease. Inflamm Bowel Dis 2011; 17: E67-E68.
9. Cabezuelo JB, Egea JP, Ramos F, Torrella E, Muray S, Alcazar C. Infliximab in the treatment of amyloidosis secondary to Crohn's disease. Nefrologia 2012; 32: 385-388.
10. Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003; 48: 2019-2024.
11. Saitoh O, Kojima K, Teranishi T, et al. Renal amyloidosis as a late complication of Crohn's disease: a case report and review of the literature from Japan. World J Gastroenterol 2000; 6: 461-464.
12. Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol 2008; 103: 776-787.
13. Cucino C, Sonnenberg A. The comorbid occurrence of other diagnoses in patients with ulcerative colitis and Crohn's disease. Am J Gastroenterol 2001; 96: 2107-2112.
14. Lowdell CP, Shousha S, Parkins RA. The incidence of amyloidosis complicating inflammatory bowel disease. A prospective survey of 177 patients. Dis Colon Rectum 1986; 29: 351-354.
15. Rashid H, Blake D, Gokal R, Gooptu D, Kerr DN. The association of renal amyloidosis with regional enteritis (Crohn's disease)--report of two cases and review of the literature. Clin Nephrol 1980; 14: 154-157.
16. Garrido-Serrano A, Guerrero-Igea JF, Hierro-Guilmain C, Ruiz-Lupiañez E, Palomo Gil S. Respuesta favorable a la colchicina en la amiloidosis secundaria a la enfermedad inflamatoria intestinal. Gastroenterol Hepatol 2001; 24: 196-198.
17. Day DW, Jass JR, Price AB, et al. Inflammatory disorders of the small intestine. In: Morson and Dawson's gastrointestinal pathology. 4th Edn, Oxford: Blackwell Scientific, 2003: 272-323.
18. Barbier M, Vidal H, Desreumaux P, et al. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol 2003; 27: 987-991.
19. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003; 14: 561-566.
20. Bedford PA, Todorovic V, Westcott ED, et al. Adipose tissue of human omentum is a major source of dendritic cells, which lose MHC Class II and stimulatory function in Crohn's disease. J Leukoc Biol 2006; 80: 546-554.
21. Bulum T, Prkacin I, Cavric G, et al. Secondary (AA) amyloidosis in Crohn's disease. Acta Med Croatica 2011; 65: 271-278.
22. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-2371.
23. Lovat LB, Madhoo S, Pepys MB, Hawkins PN. Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease. Gastroenterology 1997; 112: 1362-1365.
24. Kofman T, Grimbert P, Canouï-Poitrine F, et al. Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter study. Am J Transplant 2011; 11: 2423-2431.